Conbercept (KH-902) for the treatment of neovascular age-related macular degeneration

Expert Review of Clinical Pharmacology

Volumn 8, Issue 5, 2015, Pages 541-548

  Nguyen, Thanh T ^a   Guymer, Robyn ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Aflibercept; Age related macular degeneration; Bevacizumab; Conbercept; Pegaptanib; Ranibizumab

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; CONBERCEPT; PEGAPTANIB; RANIBIZUMAB; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; ANGIOGENESIS INHIBITOR; HYBRID PROTEIN; KH902 FUSION PROTEIN; VASCULOTROPIN A;

AGE RELATED MACULAR DEGENERATION; ARTICLE; CHINA; DISEASE COURSE; DRUG APPROVAL; FOOD AND DRUG ADMINISTRATION; HUMAN; MULTICENTER STUDY (TOPIC); PATHOGENESIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; RETINA BLOOD VESSEL; RETINA NEOVASCULARIZATION; ANIMAL; ANTAGONISTS AND INHIBITORS; CHOROIDAL NEOVASCULARIZATION; MACULAR DEGENERATION; PATHOLOGY;

ANGIOGENESIS INHIBITORS; ANIMALS; CHOROIDAL NEOVASCULARIZATION; DISEASE PROGRESSION; HUMANS; MACULAR DEGENERATION; RECOMBINANT FUSION PROTEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84940614337     PISSN: 17512433     EISSN: 17512441     Source Type: Journal    
DOI: 10.1586/17512433.2015.1075879     Document Type: Article

References (81)

1. WHO. Priority eye diseases: Main causes of visual impairment. Available from: www. who. int/blindness/causes/priority/en/ [Last accessed March 2015]
2. Wong WL, Su X, Li X, et al. Global prevalence of age-related macular degeneration and disease burden projection for. 2020 and 2040: A systematic review and meta-analysis. Lancet Glob Health 2014; 2(2): e106-16
3. Ferris FL 3rd, Wilkinson CP, Bird A, et al. Clinical classification of age-related macular degeneration. Ophthalmol 2013; 120(4): 844-51
4. Buschini E, Fea AM, Lavia CA, et al. Recent developments in the management of dry age-related macular degeneration. Clin Ophthalmol 2015; 9: 563-74
5. Bressler SB. Introduction: Understanding the role of angiogenesis and antiangiogenic agents in age-related macular degeneration. Ophthalmol 2009; 116(10 Suppl): S1-7
6. Ferris FL 3rd, Fine SL, Hyman L. Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol 1984; 102(11): 1640-2
7. Laser photocoagulation of subfoveal neovascular lesions of age-related macular degeneration. Updated findings from two clinical trials. Macular Photocoagulation Study Group. Arch ophthalmol 1993; 111(9): 1200-9
8. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006; 355(14): 1432-44
9. Solomon SD, Lindsley K, Vedula SS, et al. Anti-vascular endothelial growth factor for neovascular age-related macular degeneration. Cochrane Database Syst Rev 2014; 8: CD005139
10. Ferrara N. Vascular endothelial growth factor and age-related macular degeneration: from basic science to therapy. Nat Med 2010; 16(10): 1107-11
11. Michaelson IC. The mode of development of the vascular system of the retina with some observations on its significance for certain retinal disorders. Trans Ophthalmol Soc UK 1948; 68: 137-80
12. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285(21): 1182-6
13. Ferrara N, Fujii DK, Goldsmith PC, et al. Transport epithelial characteristics of cultured bovine pituitary follicular cells. Am J Physiol 1987; 252(3 Pt 1): E304-312
14. Ferrara N, Henzel WJ. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun 1989; 161(2): 851-8
15. Leung DW, Cachianes G, Kuang WJ, et al. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989; 246(4935): 1306-9
16. Keck PJ, Hauser SD, Krivi G, et al. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science 1989; 246(4935): 1309-12
17. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 2004; 25(4): 581-611
18. Houck KA, Leung DW, Rowland AM, et al. Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. J Biol Chem 1992; 267(36): 26031-7
19. Ferrara N. Binding to the extracellular matrix and proteolytic processing: two key mechanisms regulating vascular endothelial growth factor action. Mol Biol Cell 2010; 21(5): 687-90
20. Lee S, Jilani SM, Nikolova GV, et al. Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors. J Cell Biol 2005; 169(4): 681-91
21. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002; 420(6917): 860-7
22. Rakic JM, Lambert V, Devy L, et al. Placental growth factor, a member of the VEGF family, contributes to the development of choroidal neovascularization. Invest Ophthalmol Vis Sci 2003; 44(7): 3186-93
23. Carmeliet P, Moons L, Luttun A, et al. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med 2001; 7(5): 575-83
24. Malik AK, Baldwin ME, Peale F, et al. Redundant roles of VEGF-B and PlGF during selective VEGF-A blockade in mice. Blood 2006; 107(2): 550-7
25. Kim KJ, Cho CS, Kim WU. Role of placenta growth factor in cancer and inflammation. Exp Mol Med 2012; 44(1): 10-19
26. Luttun A, Tjwa M, Moons L, et al. Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat Med 2002; 8(8): 831-40
27. Park JE, Chen HH, Winer J, et al. Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR. J Biol Chem 1994; 269(41): 25646-54
28. Roy H, Bhardwaj S, Babu M, et al. Adenovirus-mediated gene transfer of placental growth factor to perivascular tissue induces angiogenesis via upregulation of the expression of endogenous vascular endothelial growth factor-A. Hum Gene Ther 2005; 16(12): 1422-8
29. de Vries C, Escobedo JA, Ueno H, et al. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 1992; 255(5047): 989-91
30. Terman BI, Dougher-Vermazen M, Carrion ME, et al. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem Biophys Res Commun 1992; 187(3): 1579-86
31. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003; 9(6): 669-76
32. Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992; 359(6398): 843-5
33. Adamis AP, Miller JW, Bernal MT, et al. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol 1994; 118(4): 445-50
34. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994; 331(22): 1480-7
35. Okamoto N, Tobe T, Hackett SF, et al. Transgenic mice with increased expression of vascular endothelial growth factor in the retina: A new model of intraretinal and subretinal neovascularization. Am J Pathol 1997; 151(1): 281-91
36. Tobe T, Okamoto N, Vinores MA, et al. Evolution of neovascularization in mice with overexpression of vascular endothelial growth factor in photoreceptors. Invest Opthalmol Vis Sci 1998; 39(1): 180-8
37. Schwesinger C, Yee C, Rohan RM, et al. Intrachoroidal neovascularization in transgenic mice overexpressing vascular endothelial growth factor in the retinal pigment epithelium. Am J Pathol 2001; 158(3): 1161-72
38. Baffi J, Byrnes G, Chan CC, Csaky KG. Choroidal neovascularization in the rat induced by adenovirus mediated expression of vascular endothelial growth factor. Invest Opthalmol Vis Sci 2000; 41(11): 3582-9
39. Spilsbury K, Garrett KL, Shen WY, et al. Overexpression of vascular endothelial growth factor (VEGF) in the retinal pigment epithelium leads to the development of choroidal neovascularization. Am J Pathol 2000; 157(1): 135-44
40. Wang F, Rendahl KG, Manning WC, et al. AAV-mediated expression of vascular endothelial growth factor induces choroidal neovascularization in rat. Invest Opthalmol Vis Sci 2003; 44(2): 781-90
41. Kliffen M, Sharma HS, Mooy CM, et al. Increased expression of angiogenic growth factors in age-related maculopathy. Br J Ophthalmol 1997; 81(2): 154-62
42. Grossniklaus HE, Ling JX, Wallace TM, et al. Macrophage and retinal pigment epithelium expression of angiogenic cytokines in choroidal neovascularization. Mol Vis 2002; 8: 119-26
43. Lopez PF, Sippy BD, Lambert HM, et al. Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes. Invest Opthalmol Vis Sci 1996; 37(5): 855-68
44. Lim JI, Spee C, Hangai M, et al. Neuropilin-1 expression by endothelial cells and retinal pigment epithelial cells in choroidal neovascular membranes. Am J Ophthalmol 2005; 140(6): 1044-50
45. Krzystolik MG, Afshari MA, Adamis AP, et al. Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. Arch Ophthalmol 2002; 120(3): 338-46
46. Lee JH, Canny MD, De Erkenez A, et al. A therapeutic aptamer inhibits angiogenesis by specifically targeting the heparin binding domain of VEGF165. Proc Natl Acad Sci USA 2005; 102(52): 18902-7
47. Eyetech Study G. Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration. Retina 2002; 22(2): 143-52
48. Gragoudas ES, Adamis AP, Cunningham ET Jr, et al. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004; 351(27): 2805-16
49. Colquitt JL, Jones J, Tan SC, et al. A. Ranibizumab and pegaptanib for the treatment of age-related macular degeneration: A systematic review and economic evaluation. Health Technol Assess 2008; 12(16): iii-v
50. Singerman LJ, Masonson H, Patel M, et al. Pegaptanib sodium for neovascular age-related macular degeneration: third-year safety results of the VEGF Inhibition Study in Ocular Neovascularisation (VISION) trial. Br J Ophthalmol 2008; 92(12): 1606-11
51. Chen Y, Wiesmann C, Fuh G, et al. Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen. J Mol Biol 1999; 293(4): 865-81
52. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355(14): 1419-31
53. Boyer DS, Heier JS, Brown DM, et al. A Phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration. Ophthalmol 2009; 116(9): 1731-9
54. Mitchell P, Korobelnik JF, Lanzetta P, et al. Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials. Br J Ophthalmol 2010; 94(1): 2-13
55. Group CR, Martin DF, Maguire MG, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011; 364(20): 1897-908
56. Comparison of Age-related Macular Degeneration Treatments Trials Research G. Martin DF, Maguire MG, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmol 2012; 119(7): 1388-98
57. Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nature Rev Drug Discov 2004; 3(5): 391-400
58. Presta LG, Chen H, O'Connor SJ, et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997; 57(20): 4593-9
59. Meyer CH, Holz FG. Preclinical aspects of anti-VEGF agents for the treatment of wet AMD: ranibizumab and bevacizumab. Eye 2011; 25(6): 661-72
60. Tufail A, Patel PJ, Egan C, et al. Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double masked study. Bmj 2010; 340: c2459
61. Patel PJ, Bunce C, Tufail A; Investigators ABCT. A randomised, double-masked phase III/IV study of the efficacy and safety of Avastin(R) (Bevacizumab) intravitreal injections compared to standard therapy in subjects with choroidal neovascularisation secondary to age-related macular degeneration: clinical trial design. Trials 2008; 9: 56
62. Chakravarthy U, Harding SP, Rogers CA, et al. Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Lancet 2013; 382(9900): 1258-67
63. Holash J, Davis S, Papadopoulos N, et al. VEGF-Trap: A VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA 2002; 99(17): 11393-8
64. Chappelow AV, Kaiser PK. Neovascular age-related macular degeneration: Potential therapies. Drugs 2008; 68(8): 1029-36
65. Keane PA, Sadda SR. Development of Anti-VEGF Therapies for Intraocular Use: A Guide for Clinicians. J Ophthalmol 2012; 2012: 483034
66. Nork TM, Dubielzig RR, Christian BJ, et al. Prevention of experimental choroidal neovascularization and resolution of active lesions by VEGF trap in nonhuman primates. Arch Ophthalmol 2011; 129(8): 1042-52
67. Saishin Y, Saishin Y, Takahashi K, et al. VEGF-TRAP(R1R2) suppresses choroidal neovascularization and VEGF-induced breakdown of the blood-retinal barrier. J Cell Physiol 2003; 195(2): 241-8
68. Cao J, Zhao L, Li Y, et al. A subretinal matrigel rat choroidal neovascularization (CNV) model and inhibition of CNV and associated inflammation and fibrosis by VEGF trap. Invest Opthalmol Vis Sci 2010; 51(11): 6009-17
69. Heier JS, Brown DM, Chong V, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmol 2012; 119(12): 2537-48
70. Zhang M, Yu D, Yang C, et al. The pharmacology study of a new recombinant human VEGF receptor-fc fusion protein on experimental choroidal neovascularization. Pharm Res 2009; 26(1): 204-10
71. Shinkai A, Ito M, Anazawa H, et al. Mapping of the sites involved in ligand association and dissociation at the extracellular domain of the kinase insert domain-containing receptor for vascular endothelial growth factor. J Biol Chem 1998; 273(47): 31283-8
72. Krader CG. Novel anti-VEGF agent approved in China may reduce injection frequency. Ophthalmol Times 2015. [Epub ahead of print]
73. Zhang M, Zhang J, Yan M, et al. Recombinant anti-vascular endothelial growth factor fusion protein efficiently suppresses choridal neovasularization in monkeys. Mol Vis 2008; 14: 37-49
74. Wang Q, Li T, Wu Z, et al. Novel VEGF decoy receptor fusion protein conbercept targeting multiple VEGF isoforms provide remarkable anti-angiogenesis effect in vivo. PLoS ONE 2013; 8(8): e70544
75. Chen X, Li J, Li M, et al. KH902 suppresses high glucose-induced migration and sprouting of human retinal endothelial cells by blocking VEGF and PlGF. Diabetes Obes Metab 2013; 15(3): 224-33
76. Stewart MJ. What are the half-lives of ranibizumab and aflibrcept (VEGF-Trap eye) in human eyes? Calculations with a mathematical model. Eye Reports 2011; 1: e5
77. Li H, Lei N, Zhang M, et al. Pharmacokinetics of a long-lasting anti-VEGF fusion protein in rabbit. Exp Eye Res 2012; 97(1): 154-9
78. Du L, Peng H, Wu Q, et al. Observation of total VEGF level in hyperglycemic mouse eyes after intravitreal injection of the novel anti-VEGF drug conbercept. Mol Vis 2015; 21: 185-93
79. Zhang M, Zhang J, Yan M, et al. A phase 1 study of KH902, a vascular endothelial growth factor receptor decoy, for exudative age-related macular degeneration. Ophthalmol 2011; 118(4): 672-8
80. Li X, Xu G, Wang Y, et al. Safety and efficacy of conbercept in neovascular age-related macular degeneration: results from a 12-month randomized phase 2 study: AURORA study. Ophthalmol 2014; 121(9): 1740-7
81. Grunwald JE, Daniel E, Huang J, et al. Risk of geographic atrophy in the comparison of age-related macular degeneration treatments trials. Ophthalmol 2014; 121(1): 150-61